Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Longitudinal Outcomes Registry of Complex Regional Pain Syndrome Type 1 (CRPS-1) in Participants Treated With Neridronate in the CRPS-RISE Trial and/or Open-Label Extension (OLE)

NCT07811362 is registered in ClinicalTrials.gov with Ambros Therapeutics, Inc. as lead sponsor.

NCT NCT07811362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07811362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Longitudinal Outcomes Registry of Complex Regional Pain Syndrome Type 1 (CRPS-1) in Participants Treated With Neridronate in the CRPS-RISE Trial and/or Open-Label Extension (OLE)
Lead sponsor
Ambros Therapeutics, Inc.
Phase
Observational
Overall status
Recruiting
Start date
September 17, 2026
Completion date
April 16, 2029
Enrollment
270 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

complex regional pain syndrome i (crps i)